Imagene AI has expanded its collaboration with Sheba Medical Center to build an oncology intelligence alliance that combines multimodal artificial intelligence with one of the largest collections of real-world cancer data. The strategic partnership, run through Sheba’s innovation arm ARC, is intended to accelerate biomarker discovery and support more personalised cancer care.

The work builds on Sheba’s existing use of Imagene AI’s non-small cell lung cancer application, which provides rapid biomarker profiling from routine biopsy images as part of a digital pathology workflow. Under the new agreement, the alliance will extend across multiple cancer types. Sheba will share access to its dataset of digitised pathology slides, omics data and longitudinal clinical records, while Imagene AI will provide its Cross Modality Intelligence Engine and Oncology Intelligence Suite for research and clinical use.

Prof Iris Barshack, head of the pathology institute at Sheba, said: “We are advancing cancer research and patient care by integrating innovation into daily practice. Expanding our collaboration with Imagene AI and adopting their best-in-class biomarker discovery platform empowers our pathologists and care teams to analyse multimodal real-world data, independently develop AI applications, and move faster from hypothesis to validated signal across multiple cancers.”

Imagene AI said its platform can support discovery even within small clinical cohorts, enabling predictive modelling and biomarker identification from varied data sources. Its proprietary data lake now integrates more than 3.5 million digitised pathology slides alongside other real-world evidence, creating what the company describes as a comprehensive oncology intelligence infrastructure.

Dean Bitan, co-founder and chief executive of Imagene AI, added: “Together we bridge clinical evidence with cross-modality AI to derive actionable insights, enable multimodal discovery at scale, and support evidence generation that brings precision oncology closer to patients.”

The alliance is also seen as a way to support trial design and translational research, with applications in cohort enrichment, protocol planning and predictive modelling. According to the partners, insights generated through the combined platform will be fully traceable, de-identified and managed under institutional governance frameworks.

Prof Eyal Zimlichman, founder and director of ARC and chief innovation, transformation and AI officer at Sheba, said: “Prof Barshack and her team are demonstrating how AI can transform clinical decision-making by delivering biomarker insights in minutes, enabling immediate personalised cancer treatment. This collaboration with Imagene AI exemplifies ARC’s mission to bridge clinical excellence with cutting-edge technology, creating scalable solutions that improve outcomes while establishing new standards of care for oncology worldwide.”